Hemostemix Closes $480,000 Private Placement at $0.12 per Share 
ZetrOZ Systems’ sam Wearable Ultrasound Device Offers At-Home Treatment for People with Arthritis
Sustained acoustic medicine allows people to effectively and easily manage arthritis and soft-tissue pain. TRUMBULL, CONNECTICUT / ACCESS Newswire /...
Hypha Labs Expands List of Functional Mushrooms Able to be Produced in its Revolutionary Mushroom Accelerator
Simple, In-Home Eight Day Cycle Generates Significant Yields of The World's Most Popular Mushroom Strains LAS VEGAS, NV / ACCESS...
Oragenics Q2 2025 Shareholder Update
Advancing Brain-First Recovery Platform Toward Clinical MilestonesPioneering Intranasal Therapeutics for Concussion SARASOTA, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Oragenics,...
Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update
Mipletamig's 85% frontline AML remission rate and favorable safety profile drive APVO's differentiated CD3 portfolio expansion with APVO455, a Nectin-4...
Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study
MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing...
Safety Shot Announces Strategic Alliance with Bonk Founding Contributors, Initiating BONK Treasury Strategy
Company to Receive $25 Million in BONK Tokens from Founding Contributors of BONK, Establishing a New Model for Public Company...
BODYWELLE Joins Forces With Sunset Padel for Wellness Meets Performance Event in Miami Beach
As padel grows in popularity, the wellness event "Strong Body, Strong Game" explores how core-focused therapies and aesthetic techniques contribute...
Full Alliance Group’s Qubitera Holdings Expands Quant Blockchain Healthcare Development Roadmap
Qubitera Holdings Charts Mid-2027 Global Launch for Quantum-Safe EHR/EMR PlatformTAMPA, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Full Alliance Group,...
Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025
COPENHAGEN, Denmark, August 11, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered...
Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025
COPENHAGEN, Denmark, August 11, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered...
Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results
- Released positive topline data from the VIRAGE Phase 2b study of VCN-01 (zabilugene almadenorepvec); expanded data to be presented...
vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin
HIGH POINT, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the...
4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
4D-150 Phase 3 program in wet AMD advancing ahead of plan, with expected 4FRONT-1 data readout accelerated to H1 2027...
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
CONSHOHOCKEN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate...
ArriVent BioPharma Reports Second Quarter 2025 Financial Results
Positive interim Phase 1b update underscores firmonertinib’s potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected...
Inspire Medical Systems, Inc. Board Authorizes Share Repurchase Program
MINNEAPOLIS, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the company), a medical technology...
ProPhase Labs Inc. to Present Second Quarter 2025 Financial Results on August 13, 2025
UNIONDALE, NY, Aug. 11, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation...
Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
Presentation of interim analysis from approximately 25 six-month evaluable BCG-Unresponsive patients in the ongoing ADVANCED-2 trial expected at a medical...
IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed
Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients...
Catheter Precision, Inc. Reports Results of Operations for Second Quarter 2025
Revenue Increased 128% Year Over Year and 48% SequentiallyFORT MILL, S.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc....